Compare CSBR & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | SRTS |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 79.3M |
| IPO Year | 1986 | 2016 |
| Metric | CSBR | SRTS |
|---|---|---|
| Price | $7.57 | $5.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | 5.3K | ★ 122.2K |
| Earning Date | 03-10-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $58,424,000.00 | $35,609,000.00 |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $11.51 | $29.12 |
| P/E Ratio | $44.07 | ★ N/A |
| Revenue Growth | ★ 9.06 | N/A |
| 52 Week Low | $5.59 | $3.03 |
| 52 Week High | $11.99 | $9.08 |
| Indicator | CSBR | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 64.08 |
| Support Level | $6.62 | $4.64 |
| Resistance Level | $7.45 | $5.36 |
| Average True Range (ATR) | 0.31 | 0.38 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 88.39 | 73.53 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.